 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Home |
Where do I go?
AIDA Participating Clinical Centers - Denmark
Screening and regular visits can occur at any of our Participating Clinical Centers in Denmark. For more information, contact:
Thomas Mandrup-Paulsen
tmpo@steno.dkSteno Diabetes Center
2 Niels Steensensvej
2820 Gentofte
DenmarkP: +45 4443 9101
Anne Frederiksen
af08@bbh.regionh.dkP: 0045 20912404
Joan Bach Nielsen
joanni@rm.dkP: 0045 89497575
Mette Pilegaard Rasmussen
mpr@rn.dkP: +45 99 32 61 56
Birger Thorsteinsson Overlæge, dr. med.
bith@hih.regionh.dkTlf. direkte: 48 29 74 53
Mobil: 51 52 59 13
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
